Hainan Poly Pharm Co Ltd. Stock Analysis 300630.SZ

Hainan Poly Pharm.Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Haikou, Hainan and currently employs 1,565 full-time employees. The company went IPO on 2017-03-28. The firm operates five segments. The Anti-Allergic segment is engaged in the production of desloratadine dispersible tablets, desloratadine dry suspension and desloratadine tablets. The Antibiotic segment provides levofloxacin hydrochloride capsules and azithromycin dry suspension for the treatment of bacterial infections. The Nonsteroidal Anti-inflammatory Drugs segment provides diclofenac sodium enteric-coated sustained-release capsule products for the treatment of arthritis and dysmenorrhea. The Digestive segment is involved in providing trimebutine maleate tablets to treat abdominal pain, diarrhea, and irritable bowel syndrome. The firm also operates Other segment.